One way investors can reduce risk is by buying assets trading at a discount to their intrinsic value. Several metrics can be used to determine the value of a business, including the price/earnings (p/e) and price-to-book value (p/b) ratios. Two others are Ebitda (earnings before interest, tax and amortisation) and Enterprise Value-to-Ebitda. The process can be more complex if a company has several operating divisions, which may have different attributes and prospects. The sum of private market valuations – the value that a trade or private-equity buyer would pay to acquire control – for each division may be higher than the valuation of the whole company, producing a discount to a “sum of the parts” valuation.
These discounts can narrow for several reasons. The stockmarket, driven by news or a shift in sentiment, can change its view of the valuation of the company; boards can unlock shareholder value by disposing of one or more divisions; or an investor identifies the opportunity and bids for the company. Below are three examples of smaller British firms that we believe are trading at notable discounts to their potential sum-of-the parts valuations.
A pharma group ripe for partition
Clinigen (Aim: CLIN), a pharmaceutical services and products group, has three divisions, built up through mergers and acquisitions (M&A) since its initial public offering in 2014. The shares trade at a forward p/e multiple of ten compared with a five-year average of 16. While there is some logic in keeping its three divisions together, each would appeal to different trade buyers. In our view, the current valuation is sufficiently attractive to interest a financial bidder, who could either integrate the divisions further or undertake a controlled break-up over time.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Cash-rich chemicals
Elementis (LSE: ELM) is a speciality chemicals firm with three “core” divisions and several smaller business units. There is some customer overlap among the core businesses. The current rating of ten times forward earnings is depressed owing to the impact of Covid-19 on its sales and relatively high borrowings. But these will fall over time as the company is very cash-generative. Disposal of one of the smaller, non-core business units would accelerate debt reduction, simplify the story and support a share-price rerating.
Making money in a media niche
Euromoney Institutional Investor (LSE: ERM) is a niche media firm providing companies with financial information. It consists of three divisions. The jewel in its crown is its pricing division, which is based on a subscription model and has grown well over recent years. M&A multiples for similar assets imply that one of the other two divisions is being completely overlooked by the market. Euromoney postponed plans to sell the asset management division earlier this year, but we suspect it will revisit this decision.
Private equity has acquired similar business-media companies over the last couple of decades. The forward p/e is just over 14, assuming some recovery from the trough. We believe that Euromoney’s profit recovery will continue for several years and the stock could again trade at its peak of £15 within four years, implying ample upside from here. The company has no debt and the capacity to pay a good dividend.
-
A junior ISA could turn your child’s pocket money into thousands of poundsPersuading your child to put their pocket money in a junior ISA might be difficult, but the pennies could quickly grow into pounds – and teach them a valuable lesson about money
-
Cost of Christmas dinner jumps 6.5% as grocery price inflation rises againThe average Christmas dinner for four now costs £32.57 as grocery price inflation increases - but what does it mean for interest rates?
-
Share buybacks rise in the UK – what effect will it have?Share buybacks are gaining popularity in the UK – good news for investors
-
Is now the time to buy Marshalls?Former market darling Marshalls, a landscaping and building products supplier, looks too cheap. Is it time to buy this once-admired stock?
-
Top UK stocks with healthy cash flows and dividend yieldsThree promising UK stocks according to Alan Dobbie, co-manager, Rathbone Income Fund
-
Warren Buffet invests in Domino’s – should you buy?What makes Domino's a compelling investment for Warren Buffet's Berkshire Hathaway, and should you buy the UK-listed takeaway pizza chain?
-
4Imprint makes a strong impression – should you buy?4Imprint, a specialist in marketing promotional products, is the leader in a fragmented field
-
Invest in Glencore: a cheap play on global growthGlencore looks historically cheap, yet the group’s prospects remain encouraging
-
How to save the dying UK stock marketThe UK stock market is in long-term decline. To fix that, we must first recognise why equity markets exist and who they should serve
-
Should you invest in Trainline?Ticket seller Trainline offers a useful service – and good prospects for investors
